William Blair on Neurogene (NGNE): dosing update further de-risks NGN-401 profile
William Blair analyst Sami Corwin reiterated an Outperform rating on Neurogene (NASDAQ: NGNE)The analyst commented, "We view Neurogene’s continued progress ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
